Type 2 Diabetes

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

In this episode, hosts explore technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies in the INHALE-3 trial.

Researchers uncover a mechanism of insulin resistance in obese adolescents, paving the way for potential interventions to prevent type 2 diabetes.

Hosts break down their biggest takeaways and detail their favorite sessions from the AACE 2025 annual meeting.

In this episode, hosts explore real-world data on Beta Bionics' iLet automated insulin delivery system for diabetes management.

Hosts explore Luna Diabetes automated insulin delivery system, designed to enhance sleep and improve glucose control for people with diabetes who use pens.

Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.

New data reveal tirzepatide significantly outperforms semaglutide in weight loss.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction.

In this episode, hosts explore the findings of the Catalyst trial on hypercortisolism and its impact on type 2 diabetes.

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

The FDA cleared the expanded indication for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.

In this episode, experts discuss practical guidance for screening for presymptomatic type 1 diabetes with Rifka Schulman-Rosenbaum, MD.

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.